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ABSTRACT
This prospective study determined the antibiotic susceptibility of 164 isolates of Escherichia coli from the
urine of 164 patients (112 female, 52 male; mean age of 54.12 years) with community-acquired urinary
tract infection (UTI). Half of the isolates were from uncomplicated UTI and half from complicated UTI
(52 males and 34 females). Overall, 57.3% of isolates were resistant to ampicillin, 25% to co-trimoxazole,
20.1% to nalidixic acid, 14% to norﬂoxacin and ciproﬂoxacin, and 0% to fosfomycin and nitrofurantoin.
Of the 82 isolates from complicated UTI, 16 (19.5%) were resistant to norﬂoxacin and ciproﬂoxacin,
compared with seven (8.5%) from uncomplicated UTI (p 0.043). Isolates from patients aged >50 years
were signiﬁcantly more resistant than those from patients aged <50 years for nalidixic acid (p 0.007) and
the ﬂuoroquinolones tested (p 0.015). Resistance to ﬂuoroquinolones was 25% (13 ⁄ 52) in males and 9%
(10 ⁄ 112) in females (p 0.006). For patients with and without previous antimicrobial therapy, there was a
signiﬁcant difference only for resistance to nalidixic acid (p < 0.001) and the ﬂuoroquinolones (p 0.011).
There were adequate susceptibility rates to fosfomycin, nitrofurantoin and the ﬂuoroquinolones for
empirical use in the treatment of acute uncomplicated UTI. In order to interpret cumulative
susceptibility data from the primary healthcare setting, it is necessary to take into account the type of
UTI (uncomplicated vs. complicated), previous antimicrobial therapy, and the sex and age of each
patient.
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INTRODUCTION
Acute uncomplicated cystitis is a signiﬁcant
problem in healthy non-pregnant women [1], with
c.7 million community-acquired uncomplicated
urinary tract infections (UTIs) ⁄ year in women in
the USA [2]. In a recent prospective study in the
USA, the incidence in young women was
0.5–0.7 ⁄person ⁄year [3]. Among outpatients,
Escherichia coli is the primary urinary tract patho-
gen, accounting for 75–90% of isolates from
uncomplicated UTI [4]. In many cases, acute
uncomplicated UTI in women is managed effect-
ively and safely by empirical antibiotic therapy
without the need for a urine culture. The rationale
for this approach is based on the narrow and
predictable spectrum of aetiological agents and
their susceptibility patterns [5]. Laboratory testing
is normally undertaken only when empirical
therapy fails.
Knowledge of local susceptibility trends is an
important consideration when selecting empirical
therapy for UTI. The Infectious Diseases Society of
America (IDSA) recommends that physicians
obtain information on local resistance rates, and
that ongoing surveillance be conducted to monitor
changes in the susceptibility of uropathogens [6].
Numerous studies have demonstrated high
and ⁄ or increasing antibiotic resistance levels in
E. coli causing community-acquired UTI [7–20],
but most in-vitro data come from laboratory-based
surveys that often do not deﬁne the sex, age,
clinical syndrome or other data of interest regard-
ing the patients from whom the urine specimens
were collected. In-vitro studies that speciﬁcally
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describe the antimicrobial susceptibilities of E. coli
UTI isolates, and analyse the results in relation to
demographic and clinical data, are limited.
In addition, because empirical therapy is being
used widely, fewer UTIs are being cultured
routinely. Thus, patients for whom culture results
are available are likely to reﬂect a selection bias
toward complications, recent treatment, recur-
rence of infection or suspected resistance. Thus,
laboratory samples examined routinely may over-
estimate the true levels of antibiotic resistance in
the community [21–24].
It is necessary to use new strategies to obtain
more accurate data. In the emergency service of our
hospital, nearly all UTIs treated are community-
acquired, and a urine culture is performed
routinely on suspicion of UTI. In addition, the
Emergency Service sees a greater number of com-
munity-acquired complicated UTIs than are seen
by ageneral practitioner,whichpermits a statistical
comparison according to the type of UTI (compli-
cated vs. uncomplicated). The present study
assessed the antibiotic resistance of E. coli from
community-acquired UTI in relation to demogra-
phic andclinical data, and the results obtainedwere
comparedwith those obtained in 2002 for unselect-
ed isolates from the urine samples of outpatients.
MATERIALS AND METHODS
This prospective study included 164 isolates of E. coli from the
urine of 164 patients with community-acquired UTI diagnosed
in the Emergency Service of the Hospital de Mo´stoles (Madrid,
Spain) between March 2002 and January 2003.
Susceptibility to ampicillin, gentamicin, fosfomycin, nitrof-
urantoin, cefazolin, nalidixic acid, norﬂoxacin, ciproﬂoxacin,
and trimethoprim-sulphamethoxazole (co-trimoxazole) was
determined using doubling dilutions in Mueller-Hinton broth
in a commercially available microdilution system (Wider;
Francisco Soria Melguizo SA, Madrid, Spain) [25]. The panels
were inoculated with a standardised inoculum using a rehyd-
rator-inoculator according to the guidelines provided by the
manufacturer. The inoculum was prepared with the Prompt
inoculation system (Francisco Soria Melguizo SA). After over-
night incubation, the panels were introduced into the Wider
system, which comprises a reader module and a data analysis
module. Growth parameters in susceptibility testing wells were
analysed in comparison with those in positive and negative
control wells. The MIC of each antibiotic was deﬁned as the
lowest concentration with an absence of bacterial growth. For
categorisation purposes, MICs were interpreted by NCCLS
guidelines [26]. Intermediate and resistant results were
grouped together for data analysis. Quality control was assured
by including E. coli ATCC 25922 in every batch. All MIC
determinations for this strain were within the ranges given by
NCCLS for the antibiotics included in this study.
The clinical records of the 164 patients were reviewed to
obtain demographic data (age and sex) and clinical data that
enabled classiﬁcation of the UTI as complicated or uncompli-
cated. Uncomplicated UTI refers to infection in a structurally
and neurologically normal urinary tract. Complicated UTI
refers to infection in a urinary tract with abnormalities. Cystitis
describes the syndrome involving dysuria, frequency, urgency,
and occasionally, suprapubic tenderness. Acute pyelonephritis
describes the clinical syndrome characterised by ﬂank pain or
tenderness, or both, and fever, often associated with dysuria,
urgency and frequency [27]. Antimicrobial therapy within the
preceding 3 months was also recorded.
Differences in antibiotic resistance between different patient
groups, together with calculation of the odds ratio (OR) and
95% conﬁdence interval (CI), were analysed by the v-square
test or Fisher’s exact test using SPSS software v.9.0 (SPSS
Inc., Chicago, IL, USA). A two-tailed p value of £0.05 was
considered signiﬁcant. Data were obtained from the hospital
laboratory concerning the sensitivity of E. coli isolates from
outpatient urine samples during the year 2002.
RESULTS
The 164 E. coli urinary isolates were from 112
women and 52 males (mean age of 54.12 years; SD
21.15 years; range 17–91 years), with 82 (50%)
from uncomplicated UTI (82 females; mean age,
46.34 years; SD 22.1 years) and 82 (50%) from
complicated UTI (52 males and 34 females; mean
age, 61.9 years; SD 17.02 years). Of the 82 patients
with complicated UTI, ﬁve (6.1%) presented with
kidney and urethral calculus, 13 (15.8%) with
disorders of the urinary tract (11 anatomical and
two functional), eight (9.8%) had urinary cathe-
ters, 14 (17.1%) suffered from diabetes mellitus,
and 11 (13.4%) were immunosuppressed. Of the
82 women with uncomplicated UTI, 63 had acute
cystitis (mean age, 50.14 years; SD 22.88 years)
and 19 had acute pyelonephritis (mean age,
33.74 years; SD 13.18 years).
The antimicrobial resistance of the isolates is
shown in Table 1. Of the 164 isolates, 23 (14%)
were resistant to norﬂoxacin and ciproﬂoxacin. Of
the 82 isolates from complicated UTI, 16 (19.5%)
were resistant to norﬂoxacin and ciproﬂoxacin,
compared with seven (8.5%) from uncomplicated
UTI (OR 2.6; 95% CI 0.93–7.47; p 0.043). Antibi-
otic resistance to ampicillin, gentamicin, nitrofu-
rantoin, fosfomycin, cefazolin, nalidixic acid and
co-trimoxazole was also compared, but no statis-
tically signiﬁcant differences were observed.
Similarly, no statistically signiﬁcant differences
were observed for any antibiotic when resistance
in women with complicated UTI (n = 30) and
uncomplicated UTI (n = 82) was compared.
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Signiﬁcant differences for the quinolones were
found when the resistance of isolates from
patients aged ‡50 years was compared with
isolates from patients aged <50 years, namely
28% (25 ⁄ 90) vs. 11% (8 ⁄ 74) (OR 3.17; 95% CI
1.25–8.3; p 0.007) for nalidixic acid, and 20%
(18 ⁄ 90) vs. 6.7% (5 ⁄ 74) (OR 3.45; 95% CI 1.12–
11.3; p 0.015) for the ﬂuoroquinolones tested.
No statistically signiﬁcant difference was found
for any antibiotic when resistance in isolates from
uncomplicatedUTIwas compared in patients aged
‡50 years (n = 29) and patients <50 years (n = 53).
Comparison of the resistance rates according to
the sex of the patient showed statistically signiﬁ-
cant differences for cefazolin (11.5% (6 ⁄ 52) in
males compared with 1.7% (2 ⁄ 112) in females;
p 0.013) and for ﬂuoroquinolones (25% (13 ⁄ 52) in
males and 9% (10 ⁄ 112) in females; p 0.006).
There were no signiﬁcant differences for any
antibiotic between women with uncomplicated
cystitis (n = 63) and those with uncomplicated
pyelonephritis (n = 19).
When patients who had received previous
antimicrobial therapy (n = 27) were compared
with those without previous antimicrobial ther-
apy (n = 137), there was a statistically signiﬁcant
difference only for resistance to nalidixic acid
(p < 0.001) and the ﬂuoroquinolones tested
(p 0.011).
Laboratory data indicated that 2061 strains of
E. coliwere isolated from outpatient urine samples
during 2002, of which 58.4% were resistant to
ampicillin, 6.1% to gentamicin, 30.7% to co-trim-
oxazole, 29.7% to nalidixic acid, 4.1% to cefazolin,
19.0% to norﬂoxacin, 19.2% to ciproﬂoxacin, 2.3%
to fosfomycin, and 1.4% to nitrofurantoin.
DISCUSSION
Knowledge of local susceptibility patterns is
important for the selection of appropriate
empirical therapy for UTI. The IDSA guidelines
recommend therapy with co-trimoxazole in set-
tings where the prevalence of resistance is <10–
20% [6]. Alternative therapy for uncomplicated
UTI in settings with >10–20% resistance to co-
trimoxazole may include a ﬂuoroquinolone, ni-
trofurantoin or fosfomycin [6].
In Spain, published data indicate a high fre-
quency of resistance to ampicillin, co-trimoxazole
and the quinolones among E. coli isolates from
outpatient urine samples [7–9,11,17,19], which
seems to indicate that these antimicrobial agents
should not be used. However, the data from the
present study indicate that ﬂuoroquinolone resist-
ance in E. coli is associated mostly with isolates
from complicated UTI and ⁄ or patients who have
received previous antibiotic therapy. The results
(8.5% resistance to ﬂuoroquinolones in isolates
from uncomplicated UTI) have important clinical
implications in the context of the empirical use of
these antimicrobial agents. Actual resistance rates
are signiﬁcantly less than those indicated by
routine pooled laboratory specimens (c.19%).
Other studies have shown that factors associated
with complicated UTI, such as abnormalities of
the urinary tract, an age of >65 years, urinary
catheterisation, and previous treatment with
quinolones, are associated independently with
infections caused by ciproﬂoxacin-resistant iso-
lates of E. coli [28]. There are clearly more uncom-
plicated than complicated UTIs [24] seen in the
primary healthcare setting than by an emergency
service, so the present results for ﬂuoroquinolone
resistance are particularly relevant in that they
provide a more accurate picture of the suscepti-
bility patterns of E. coli causing uncomplicated
UTI. Traditional surveillance data may have a
bias toward over-reporting resistance to some
antibiotics in patients with acute uncomplicated
UTI, as urine samples sent to the microbiology
laboratory by general practitioners are not repre-
Table 1. Number (%) of Escherichia
coli isolates resistant to each of the
antibiotics tested
Antibiotic
Total
(n = 164)
Complicated UTI
(n = 82)
Uncomplicated UTI
(n = 82) p
Susceptibility
breakpoint (mg ⁄L)
Ampicillin 94 (57.3%) 48 (58.5%) 46 (56.1%) NS £8
Gentamicin 4 (2.4%) 3 (3.7%) 1 (1.2%) NS £4
Fosfomycin 0 0 0 NS £64
Cefazolin 8 (4.9%) 6 (7.3%) 2 (2.4%) NS £8
Co-trimoxazole 41 (25.0%) 23 (28.0%) 18 (22.0%) NS £2 ⁄ 38
Nitrofurantoin 0 0 0 NS £32
Nalidixic acid 33 (20.1%) 21 (25.6%) 12 (14.6%) NS £16
Norﬂoxacin 23 (14.0%) 16 (19.5%) 7 (8.5%) 0.043 £4
Ciproﬂoxacin 23 (14.0%) 16 (19.5%) 7 (8.5%) 0.043 £1
NS, not signiﬁcant.
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sentative of UTI in the primary healthcare setting
[24]. A recent study [29] found that the frequency
of urinalysis requests has declined over time,
which probably corresponds with a decline in
urine culture and susceptibility testing. This
decline will have the unintended effect of decreas-
ing the amount of information available for
assessment of local resistance trends [29].
Comparing the results obtained for isolates from
uncomplicated UTIwith those obtained in 1997–98
in the same area by the same method [30], an
increase in resistance to quinolones was observed.
Increasing ﬂuoroquinolone resistance among urin-
ary E. coli has also been documented in studies in
other countries [12,18]. Indeed, in a study in the
USA, ciproﬂoxacin was the only agent studied that
demonstrated a consistent stepwise increase in
resistance from 1995 (0.7%) to 2001 (2.5%) [18]. An
increase in the prescription of ﬂuoroquinolones for
uncomplicated UTI in the USA may be contribu-
ting to this observation [29]. Based on the data from
the present study, the quinolones are currently a
valid option for empirical therapy of uncompli-
cated UTI, but careful use is recommended to
avoid the selection and spread of resistant strains.
In conclusion, data from local laboratories
exaggerate the ﬂuoroquinolone resistance prob-
lems among E. coli urine isolates from general
practice. In acute uncomplicated UTI, fosfomycin,
nitrofurantoin and the ﬂuoroquinolones show
adequate rates of susceptibility for empirical
use. For optimal interpretation of cumulative
susceptibility data in the primary healthcare
setting, it is necessary to take into account the
type of UTI (uncomplicated vs. complicated), as
well as the sex and age of each patient.
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